Linked Life Data

15775068

Source:http://linkedlifedata.com/resource/pubmed/id/15775068

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-3-18
pubmed:abstractText
PTH is a potent stimulator for both bone resorption and formation. The clinical application of PTH on osteoporosis resulted in marked increase in lumber BMD. However, the BMD in the cortical bone site was decreased by PTH administration. Furthermore, serious reduction of lumber BMD after cessation of PTH has been reported. To resolve these disadvantages of PTH treatment in osteoporosis, concurrent or sequential treatment of PTH and alendronate has been proposed. The results seemed to be promising because those modes of treatments showed significant increase in BMD at all bone sites and there was no withdraw phenomenon on BMDs after the cessation of PTH administration. Thus, the sequential or concurrent treatment of PTH and alendronate may be a powerful tool for the prevention of osteoporosis fracture.
pubmed:language
jpn
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jan
pubmed:issn
0917-5857
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
54-8
pubmed:dateRevised
2006-11-15
pubmed:year
2003
pubmed:articleTitle
[Concurrent or sequential treatment for osteoporosis with PTH and alendronates].
pubmed:affiliation
Research Institute and Practice for Involutional Diseases.
pubmed:publicationType
Journal Article, English Abstract